134 related articles for article (PubMed ID: 34652050)
1. Prognostic difficulties of men with breast cancer.
Fentiman IS
Breast J; 2021 Dec; 27(12):877-882. PubMed ID: 34652050
[TBL] [Abstract][Full Text] [Related]
2. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L
Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328
[TBL] [Abstract][Full Text] [Related]
3. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
4. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
Ottini L; Silvestri V; Rizzolo P; Falchetti M; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D
Breast Cancer Res Treat; 2012 Jul; 134(1):411-8. PubMed ID: 22527108
[TBL] [Abstract][Full Text] [Related]
6. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
Deb S; Jene N; ; Fox SB
BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
[TBL] [Abstract][Full Text] [Related]
8. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
[TBL] [Abstract][Full Text] [Related]
9. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in men.
Gethins M
J Natl Cancer Inst; 2012 Mar; 104(6):436-8. PubMed ID: 22393212
[No Abstract] [Full Text] [Related]
12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Pusina S
Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Di Bernardo MC; Matakidou A; Eisen T; Houlston RS;
Lung Cancer; 2009 Aug; 65(2):237-41. PubMed ID: 19117638
[TBL] [Abstract][Full Text] [Related]
15. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
17. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
Palli D; Falchetti M; Masala G; Lupi R; Sera F; Saieva C; D'Amico C; Ceroti M; Rizzolo P; Caligo MA; Zanna I; Ottini L
BMC Cancer; 2007 Sep; 7():170. PubMed ID: 17767707
[TBL] [Abstract][Full Text] [Related]
18. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
19. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
